3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 2/3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
73
Neoplasms
46
Squamous Cell Carcinoma of Head and Neck
45
Head and Neck Neoplasms
35
Lung Neoplasms
34
Uterine Cervical Neoplasms
27
Neoplasm Metastasis
26
Unspecified Adult Solid Tumor, Protocol Specific
24
Stomach Neoplasms
24
Ovarian Neoplasms
24
Small Cell Lung Carcinoma
21
Pancreatic Neoplasms
19
Colorectal Neoplasms
18
Cholangiocarcinoma
17
Carcinoma, Squamous Cell
17
Esophageal Neoplasms
16
Breast Neoplasms
15
Mesothelioma, Malignant
14
Melanoma
13
Urinary Bladder Neoplasms
12
Mesothelioma
11
Fallopian Tube Neoplasms
11
Carcinoma, Ovarian Epithelial
11
Sarcoma
9
Gallbladder Neoplasms
9
Esophageal Squamous Cell Carcinoma
9
Biliary Tract Neoplasms
9
Carcinoma
8
Triple Negative Breast Neoplasms
7
Recurrence
7
Interventions
pembrolizumab
2
Cyclophosphamide
2
Celecoxib
2
olaparib
1
isophosphamide mustard
1
fludarabine
1
entinostat
1
bosutinib
1
anetumab ravtansine
1
Pemetrexed
1
Imatinib Mesylate
1
Gemcitabine
1
FANG vaccine
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Thymoma
×
Cisplatin
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled